Phase I and II clinical trials of Russia's EpiVacCorona vaccine against the coronavirus show that its immunological efficacy amounts to 100 percent, consumer health watchdog Rospotrebnadzor said on Tuesday
MOSCOW (Pakistan Point News / Sputnik - 19th January, 2021) Phase I and II clinical trials of Russia's EpiVacCorona vaccine against the coronavirus show that its immunological efficacy amounts to 100 percent, consumer health watchdog Rospotrebnadzor said on Tuesday.
"Vaccine effectiveness consists of its immunological efficacy and preventive efficacy. According to results of Phase I and Phase II clinical trials, immunological efficacy of the EpiVacCorona vaccine stands at 100 percent," the watchdog said in a statement.
